Paper1314232
In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical data.
Smit EF and 8 others. Int J Cancer, 1992. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical data. Papers, record 1314232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1314232
- Cell line
- GLC-311 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical data.
- PubMed
Connected records6
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Small Cell | Major topic |
| Lung Neoplasms | Major topic |
| DNA, Neoplasm | |
| Doxorubicin | |
| Drug Screening Assays, Antitumor | |
| Female | |
| Flow Cytometry | |
| Humans | |
| Immunohistochemistry | |
| Male | |
| Middle Aged | |
| Tumor Cells, Cultured |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35267619 | Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine Pathways. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35267619 | PubMed |
| 28662214 | RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. | PLoS One | 2017 | https://conductscience.org/library/papers/28662214 | PubMed |
| 27957556 | RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key transformation-associated pathways. | Heliyon | 2016 | https://conductscience.org/library/papers/27957556 | PubMed |
| 25889998 | Insight into the role of alternative splicing within the RBM10v1 exon 10 tandem donor site. | BMC Res Notes | 2015 | https://conductscience.org/library/papers/25889998 | PubMed |
| 9765624 | The TdT-mediated dUTP nick end labeling assay precisely assesses the DNA damage in human tumor xenografts. | Jpn J Cancer Res | 1998 | https://conductscience.org/library/papers/9765624 | PubMed |
| 8094293 | Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8094293 | PubMed |
| 7948302 | P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. | Ann Hematol | 1994 | https://conductscience.org/library/papers/7948302 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1314232
GET https://conductscience.org/api/papers/v1/1314232/authors